STRICTLY PRIVATE & CONFIDENTIAL June 11, 2021 Richard Chin, M.D. Chief Executive Officer Kindred Biosciences, Inc. Burlingame, CA 94010 Dear Dr. Chin,

Exhibit 99.4

STRICTLY PRIVATE & CONFIDENTIAL

June 11, 2021

Xxxxxxx Xxxx, M.D.

Chief Executive Officer

Kindred Biosciences, Inc.

0000 Xxxxxxxx Xxxxxxx, Xxxxx #000

Xxxxxxxxxx, XX 00000

Dear Xx. Xxxx,

Reference is made to that letter agreement (the “Letter Agreement”), dated as of May 31, 2021, between Kindred Biosciences, Inc. (the “Company”) and Elanco Animal Health Incorporated (“Elanco”). In accordance with Section 7 of the Letter Agreement, the Company and Elanco hereby agree to amend the Letter Agreement as set forth below.

1. Definition of Exclusivity Period. The definition of “Exclusivity Period” in Section 2(c) of the Letter Agreement shall be amended and restated as follows:

“Exclusivity Period” means the period commencing at 12:00 a.m. New York City time on June 1, 2021 and ending at 9:30 a.m. New York City Time on June 16, 2021.

2. Other Terms. The provisions of Sections 4, 5, 6 and 7 of the Letter Agreement shall apply mutatis mutandis to this amendment.

3. Full Force and Effect. Except as specifically amended hereby, the parties hereto acknowledge and agree that all of the terms and provisions set forth in the Letter Agreement remain in full force and effect in all respects.

[Remainder of the page intentionally left blank.]

		Very truly yours,
		ELANCO ANIMAL HEALTH INCORPORATED
		By:	/s/ Xxxxx X. Xxxxxxx

		Name:	Xxxxx X. Xxxxxxx
		Title:	Executive Vice President of Innovation, Regulatory & Business Development

Agreed and accepted:
kindred biosciences, INC.
By:	/s/ Xxxxxxx Xxxx

Name:	Xxxxxxx Xxxx
Title:	CEO

[Signature page to Amendment to Exclusivity Letter]